- Tel: 858.663.9055
- Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
In 1990, a breast cancer susceptibility gene designated BRCA1 was localized to chromosome 17q. Mutations within this gene are believed to account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2 (breast cancer 2, early onset), located on chromosome 13q13.1, also confers a high incidence of breast cancer but, unlike BRCA1, does not confer a substantially elevated risk of ovarian cancer. Both BRCA1 and BRCA2 play a role in the maintainance of genome stability, particularly in the homologous recombination pathway for double-strand DNA repair. BRCA2 is regarded as a tumor suppressor gene; tumors with BRCA2 mutations exhibit loss of heterozygosity (LOH) of the wildtype allele. The protein encoded by the BRCA2 gene contains multiple copies of a 70 amino acid motif called the BRC motif. These motifs effect binding to the Rad51 recombinase, which operates in DNA repair.
Optimal dilution of the BRCA2 antibody should be determined by the researcher.
A recombinant partial protein sequence (within amino acids 200-500) from the human protein was used as the immunogen for the BRCA2 antibody.
Aliquot the BRCA2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.